Product EfficacyEncouraging launch metrics and positive views from Key Opinion Leaders on Zoetis' OA pain mAbs support strong prospects, alongside confidence in the efficacy and long-term outlook of Librela.
Product LaunchZoetis is anticipated to have strong uptake of key new products, with management's confidence reflected in robust revenue estimates, indicating potential market growth.
Safety And Regulatory StatusVeterinarian feedback suggests Librela is well-received for its benefits and safety, with low adverse events rates and routine regulatory interactions post-launch, hinting at a stable market presence.